For research use only. Not for use in humans.

Cevostamab (Anti- FcRH5 / IRTA2 / CD307e)

Synonyms: BFCR 4350A; RG 6160; RO 7187797 Cat.No.A2746 Purity:99%

Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) is a humanized IgG1-based bispecific antibody that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. MW: 145.24 kD.

Quality Control

Batch: A274601 Purity: 99% Protein concentration: 5.229mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Mechanism of Action

Description	Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) is a humanized IgG1-based bispecific antibody that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. MW: 145.24 kD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/28262555/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2249888-53-5
Molecular Weight	145.24
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.